Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
|
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [41] Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain
    Lolli, Graziano
    Battistutta, Roberto
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2013, 69 : 2161 - 2164
  • [42] Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors
    Qiao, Xue-Peng
    Wang, Xue-Ting
    Wang, Shuai
    Mu, Hong-Xia
    Wang, Qing-Shan
    Ab, Shi-Wu Chen
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 106
  • [43] Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
    Zhang, Zhimin
    Gu, Lili
    Wang, Beibei
    Huang, Wenhai
    Zhang, Yanmin
    Ma, Zhen
    Zeng, Shenxin
    Shen, Zhengrong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 808 - 817
  • [44] Discovery of selective and potent BRD4 protein degraders using Plexium's DELPhe platform.
    Parker, Gregory S.
    Toth, Julia A.
    Leriche, Geoffray
    Bailey, Simon
    Chng, Kenneth
    Fish, Sara
    Jamborcic, Aleks
    Daniele, Elizabeth
    Green, Erika
    Hocker, Michael
    Kallel, Adam
    Thompson, Peggy A.
    Brown, Steven D.
    Vijayan, Kandaswamy
    CANCER RESEARCH, 2021, 81 (13)
  • [45] Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies
    Upadhayaya, Ram S.
    Kethiri, Raghava Reddy
    Vellanki, Avanish
    Lightfoot, Jeff
    Local, Andrea
    Rice, William G.
    BLOOD, 2016, 128 (22)
  • [46] Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
    Vidler, Lewis R.
    Filippakopoulos, Panagis
    Fedorov, Oleg
    Picaud, Sarah
    Martin, Sarah
    Tomsett, Michael
    Woodward, Hannah
    Brown, Nathan
    Knapp, Stefan
    Hoelder, Swen
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 8073 - 8088
  • [47] Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer
    Liu, Jiuyu
    Huang, Jingxuan
    Wang, Kang
    Li, Yuan
    Li, Chunting
    Zhu, Yanli
    He, Xinzi
    Zhang, Yating
    Zhao, Yanfang
    Hu, Changliang
    Xi, Zhiguo
    Tong, Minghui
    Li, Zhiwei
    Gong, Ping
    Hou, Yunlei
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 101
  • [48] Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection
    Vann, Kendra R.
    Acharya, Arpan
    Jang, Suk Min
    Lachance, Catherine
    Zandian, Mohamad
    Holt, Tina A.
    Smith, Audrey L.
    Pandey, Kabita
    Durden, Donald L.
    El-Gamal, Dalia
    Cote, Jacques
    Byrareddy, Siddappa N.
    Kutateladze, Tatiana G.
    STRUCTURE, 2022, 30 (09) : 1224 - +
  • [49] Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
    Huang, Bo
    Yang, Xiao-Dong
    Zhou, Ming-Ming
    Ozato, Keiko
    Chen, Lin-Feng
    MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (05) : 1375 - 1387
  • [50] Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4
    Xiang, Wang
    Wang, Qiwei
    Ran, Kai
    Ren, Jing
    Shi, Yaojie
    Yu, Luoting
    BIOORGANIC CHEMISTRY, 2021, 115